The Experts below are selected from a list of 90 Experts worldwide ranked by ideXlab platform

Krystian Gałęcki - One of the best experts on this subject based on the ideXlab platform.

  • Experimental and theoretical investigation of bezafibratebinding to serum albumins
    Journal of Luminescence, 2016
    Co-Authors: Krystian Gałęcki, Kelsey Hunter, Gabriela Daňková, Elsy Rivera, Lw Tung, K. Mc Sherry
    Abstract:

    The purpose of this investigation was to provide insight into the possible mechanism of the intermolecular interactions between Antilipemic Agent bezafibrate and serum albumins (SAs) including human (HSA) and bovine (BSA). The aim was to indicate the most probable sight of these interactions. Both experimental (spectroscopic) and theoretical methods were applied. It was determined that bezafibrate binds to SAs in one specific binding site, the fatty acid binding site 6. The results obtained from the steady-state and time-resolved fluorescence experiments suggested that existing two distinct stable conformations of the proteins with different exposure to the quencher. The dominate conformer of HSA and BSA characterized by the Stern-Volmer quenching constant (from ratio F-0/F) equal to 1.24.10(4) and 8.48.10(3) M-1 at 298 K, respectively. The docking results and calculated thermodynamics parameters may be suggested that the binding process is spontaneous and might involve van der Waals and hydrogen bonding forces. (c) 2016 Elsevier B.V. All rights reserved.

  • Experimental and theoretical investigation of bezafibrate binding to serum albumins
    Journal of Luminescence, 2016
    Co-Authors: Krystian Gałęcki, Kelsey Hunter, Gabriela Daňková, Elsy Rivera, Lo Wing Tung, Kenneth Mc Sherry
    Abstract:

    Abstract The purpose of this investigation was to provide insight into the possible mechanism of the intermolecular interactions between Antilipemic Agent bezafibrate and serum albumins (SAs) including human (HSA) and bovine (BSA). The aim was to indicate the most probable sight of these interactions. Both experimental (spectroscopic) and theoretical methods were applied. It was determined that bezafibrate binds to SAs in one specific binding site, the fatty acid binding site 6. The results obtained from the steady-state and time-resolved fluorescence experiments suggested that existing two distinct stable conformations of the proteins with different exposure to the quencher. The dominate conformer of HSA and BSA characterized by the Stern–Volmer quenching constant (from ratio F 0 / F ) equal to 1.24·10 4 and 8.48·10 3  M −1 at 298 K, respectively. The docking results and calculated thermodynamics parameters may be suggested that the binding process is spontaneous and might involve van der Waals and hydrogen bonding forces.

Johnson, Sarah Kepple - One of the best experts on this subject based on the ideXlab platform.

  • The Effects of HMG-CoA Inhibitors (Statins) on Rheumatoid Arthritis Disease Progression: A Systematic Review
    CommonKnowledge, 2012
    Co-Authors: Johnson, Sarah Kepple
    Abstract:

    Background: Rheumatoid arthritis is a chronic, progressive autoimmune disease that erodes joint synovium and affects other body organs and vasculature. While current therapies, designed to address the impact of rheumatoid arthritis on joints, have been shown to be of benefit, the disabling and progression nature of the disease remains. In addressing the cardiovascular complications of this disease, providers may have stumbled upon another medication, a cholesterol lowering medication known as statins, which may prove beneficial for patients by decreasing inflammation and slowing disease progression. This review will examine the impact of statin medications of rheumatoid arthritis disease progression, as assessed by the DAS28. Method: An exhaustive search of the literature was conducted in Medline (Ovid) and Web of Science using the following search terms: rheumatoid arthritis, HMG Co-A inhibitor, statin, “severity of illness index”, disease progression, and treatment outcome. A search in CINAHL required the additional keywords anticholesteremic Agents and Antilipemic Agent. Studies that assessed the effect of statin medications on DAS28, an index used to assess rheumatoid arthritis severity, were included. Studies were further limited to human subjects, adults, and English language. Results: A total of 132 results were found, 17 of which were further screened using the eligibility criteria, and five studies qualified for this systematic review. Four studies are randomized clinical trials, including one crossover study, and one is a prospective cohort study. In all studies, statin medications were shown to improve specific inflammatory markers (such as swollen joint counts, tender joint counts, CRP, and ESR), however, only three studies demonstrated their improvement of the DAS28 itself. Conclusion: The results of this systematic review demonstrate a trend of decreased inflammation in rheumatoid arthritis patients relatable to statin therapy; however, the picture remains unclear as to the improvement in rheumatoid arthritis disease progression with adjuvant statin use. Keywords: rheumatoid arthritis, DAS28, disease activity, disease progression, HMG-CoA inhibitor, severity of illness, statin, treatment outcom

Palaninathan Varalakshmi - One of the best experts on this subject based on the ideXlab platform.

  • Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats.
    Molecular and cellular biochemistry, 2007
    Co-Authors: Ganapathy Amudha, Anthony Josephine, Palaninathan Varalakshmi
    Abstract:

    Cyclosporine A (CsA)-induced dyslipidemia is one of the most important risk factors for morbidity and mortality after solid organ transplantation. Reducing this side effect of CsA by dietary Agents may be safe, cost-effective, and attractive to both patients and health professionals. Hence the present study was designed to evaluate the role of DL-alpha-Lipoic acid (LA) in deteriorating the lipid abnormalities induced by CsA in rat kidney. Male albino Wistar rats were divided into four groups. CsA administered at a dose of 25 mg/kg body weight, orally for 21 days showed abnormal changes in the levels of lipoprotein fractions (LDL, HDL and VLDL) and lipid profile in both plasma and renal tissue. Significant alterations were also observed in the activities of lipid metabolizing enzymes. Co-treatment with LA (20 mg/kg body weight, oral gavage, for 21 days) reverted the levels of lipid profile (P < 0.001, P < 0.01) and lipoprotein fractions (P < 0.001, P < 0.01) to near control. The activities of lipid metabolizing enzymes also showed considerable restoration on LA supplementation. The outcome of this study provides evidence that LA (a natural metabolic antioxidant) treatment acts as a potent Antilipemic Agent against CsA-induced lipid abnormalities.

  • Beneficial effect of dl-α-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats
    Molecular and Cellular Biochemistry, 2007
    Co-Authors: Ganapathy Amudha, Anthony Josephine, Palaninathan Varalakshmi
    Abstract:

    Cyclosporine A (CsA)-induced dyslipidemia is one of the most important risk factors for morbidity and mortality after solid organ transplantation. Reducing this side effect of CsA by dietary Agents may be safe, cost-effective, and attractive to both patients and health professionals. Hence the present study was designed to evaluate the role of dl-α-Lipoic acid (LA) in deteriorating the lipid abnormalities induced by CsA in rat kidney. Male albino Wistar rats were divided into four groups. CsA administered at a dose of 25 mg/kg body weight, orally for 21 days showed abnormal changes in the levels of lipoprotein fractions (LDL, HDL and VLDL) and lipid profile in both plasma and renal tissue. Significant alterations were also observed in the activities of lipid metabolizing enzymes. Co-treatment with LA (20 mg/kg body weight, oral gavage, for 21 days) reverted the levels of lipid profile (P < 0.001, P < 0.01) and lipoprotein fractions (P < 0.001, P < 0.01) to near control. The activities of lipid metabolizing enzymes also showed considerable restoration on LA supplementation. The outcome of this study provides evidence that LA (a natural metabolic antioxidant) treatment acts as a potent Antilipemic Agent against CsA-induced lipid abnormalities.

Sarah Kepple Johnson - One of the best experts on this subject based on the ideXlab platform.

  • The Effects of HMG-CoA Inhibitors (Statins) on Rheumatoid Arthritis Disease Progression: A Systematic Review
    2012
    Co-Authors: Sarah Kepple Johnson
    Abstract:

    Background: Rheumatoid arthritis is a chronic, progressive autoimmune disease that erodes joint synovium and affects other body organs and vasculature. While current therapies, designed to address the impact of rheumatoid arthritis on joints, have been shown to be of benefit, the disabling and progression nature of the disease remains. In addressing the cardiovascular complications of this disease, providers may have stumbled upon another medication, a cholesterol lowering medication known as statins, which may prove beneficial for patients by decreasing inflammation and slowing disease progression. This review will examine the impact of statin medications of rheumatoid arthritis disease progression, as assessed by the DAS28. Method: An exhaustive search of the literature was conducted in Medline (Ovid) and Web of Science using the following search terms: rheumatoid arthritis, HMG Co-A inhibitor, statin, “severity of illness index”, disease progression, and treatment outcome. A search in CINAHL required the additional keywords anticholesteremic Agents and Antilipemic Agent. Studies that assessed the effect of statin medications on DAS28, an index used to assess rheumatoid arthritis severity, were included. Studies were further limited to human subjects, adults, and English language. Results: A total of 132 results were found, 17 of which were further screened using the eligibility criteria, and five studies qualified for this systematic review. Four studies are randomized clinical trials, including one crossover study, and one is a prospective cohort study. In all studies, statin medications were shown to improve specific inflammatory markers (such as swollen joint counts, tender joint counts, CRP, and ESR), however, only three studies demonstrated their improvement of the DAS28 itself. Conclusion: The results of this systematic review demonstrate a trend of decreased inflammation in rheumatoid arthritis patients relatable to statin therapy; however, the picture remains unclear as to the improvement in rheumatoid arthritis disease progression with adjuvant statin use.

Takashi Hitsumoto - One of the best experts on this subject based on the ideXlab platform.

  • angioscopic evaluation of stabilizing effects of an Antilipemic Agent bezafibrate on coronary plaques in patients with coronary artery disease a multicenter prospective study
    Japanese Heart Journal, 2002
    Co-Authors: Hidefumi Ohsawa, Yasumi Uchida, Yoshiharu Fujimori, Junichi Hirose, Hirofumi Noike, Keiichi Tokuhiro, Kohei Kawamura, Masahito Kanai, Hiroshi Sakuragawa, Takashi Hitsumoto
    Abstract:

    To evaluate the stabilizing effects of an Antilipemic Agent, bezafibrate, on coronary plaques, we carried out a prospective angioscopic and angiographic open trial. From April 1997 to December 1998, 24 patients underwent coronary angioscopy of plaques in non-targeted vessels during coronary interventions and then again 6 months later. The patients were divided into control (10 patients, 14 plaques) and bezafibrate (14 patients, 21 plaques) groups. Oral administration of bezafibrate (400 mg/day) was started immediately after the intervention and was continued for 6 months. The vulnerability score was determined based on the angioscopic characteristics of plaques and compared before and 6 months later. Six months later, the vulnerability score was reduced (from 1.6 to 0.8; P<0.05) in the bezafibrate group and unchanged (from 1.4 to 1.3; NS) in the control group. In the bezafibrate group, the changes in the vulnerability score were not correlated with those in % stenosis or minimal lumen diameter. The plasma total cholesterol level (T-C) was unchanged, triglyceride level (TG) was decreased, and high density lipoprotein cholesterol level (HDL-C) was increased in the bezafibrate group, but were unchanged in the control group. In the bezafibrate group, T-C and TG were decreased and HDL-C was increased in patients with a reduced vulnerability score but were unchanged in those with an unchanged score. These results indicate that 6 month administration of bezafibrate stabilizes coronary plaques and that the stabilization is not correlated with angiographic changes.

  • Angioscopic evaluation of stabilizing effects of an Antilipemic Agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.
    Japanese heart journal, 2002
    Co-Authors: Hidefumi Ohsawa, Yasumi Uchida, Yoshiharu Fujimori, Junichi Hirose, Hirofumi Noike, Keiichi Tokuhiro, Kohei Kawamura, Masahito Kanai, Hiroshi Sakuragawa, Takashi Hitsumoto
    Abstract:

    To evaluate the stabilizing effects of an Antilipemic Agent, bezafibrate, on coronary plaques, we carried out a prospective angioscopic and angiographic open trial. From April 1997 to December 1998, 24 patients underwent coronary angioscopy of plaques in non-targeted vessels during coronary interventions and then again 6 months later. The patients were divided into control (10 patients, 14 plaques) and bezafibrate (14 patients, 21 plaques) groups. Oral administration of bezafibrate (400 mg/day) was started immediately after the intervention and was continued for 6 months. The vulnerability score was determined based on the angioscopic characteristics of plaques and compared before and 6 months later. Six months later, the vulnerability score was reduced (from 1.6 to 0.8; P